Sara Weymer

Sara Weymer is Vice President, Clinical Operations, at Neomorph. She brings over 20 years of clinical development experience focusing on Phase I-III studies in oncology and neurology. She joins Neomorph from Boundless Bio, where she held the position of Vice President, Clinical Operations, and participated in the IND filing and clinical trial start-up of their two lead clinical development programs. While at Boundless, Sara had the opportunity to work on the first studies targeting extrachromosomal DNA in pan-tumor indications using precision medicine. Prior to that, Sara was at Fate Therapeutics, Inc. where she served as Executive Director and Head of Clinical Operations and oversaw the clinical implementation of 9 Fate-sponsored INDs and 6 Investigator-initiated INDs across 8 development programs. During this time Sara had the opportunity to pioneer the clinical development of IPSC-derived NK and T-cell therapies in various hematologic and solid tumor indications. Sara’s early career included positions of increasing responsibility with experience in all types of development organizations including ZZ Biotech, Biogen Idec, Metabasis Therapeutics, Altana Pharma, and Parexel. Sara holds a Bachelor of Science in nutritional biochemistry from Cornell University.